Literature DB >> 26781552

Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.

James M Wilkins1, Brent P Forester2.   

Abstract

Neuropsychiatric symptoms (NPS) of dementia including agitation, depression, and psychosis are common and debilitating facets of the disease process. Despite the significant impact of these symptoms on both individuals with dementia and their caregivers, safe and effective treatment options are lacking. From a pharmacological approach, antipsychotics have historically been the treatment of choice, but these medications are only modestly effective with significant adverse effects. Behavioral and psychosocial interventions have been shown to be effective but are difficult to implement in routine clinical practice. SSRI medications have been investigated as an alternative psychopharmacological approach based on evidence that the serotoninergic system is involved in the etiology of NPS in dementia. The evidence base for using SSRI medications in the treatment of NPS is growing, but the applicability of research findings to the utility of SSRIs in general in routine clinical practice is not entirely clear at this point. Further studies of a variety of SSRI medications in targeting NPS are needed to make a more definitive assessment of the efficacy of these medications in the relief of NPS.

Entities:  

Keywords:  Antidepressant; Dementia; Neuropsychiatric symptoms; SSRI

Mesh:

Substances:

Year:  2016        PMID: 26781552     DOI: 10.1007/s11920-015-0656-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  39 in total

1.  Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia.

Authors:  S Gaber; S Ronzoli; A Bruno; A Biagi
Journal:  Arch Gerontol Geriatr Suppl       Date:  2001

Review 2.  Phenomenology of Depression in Alzheimer's Disease.

Authors:  Filipa Novais; Sergio Starkstein
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study.

Authors:  K Olafsson; S Jørgensen; H V Jensen; A Bille; P Arup; J Andersen
Journal:  Acta Psychiatr Scand       Date:  1992-06       Impact factor: 6.392

4.  Sertraline for the treatment of depression in Alzheimer disease.

Authors:  Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-02       Impact factor: 4.105

5.  Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

Authors:  Daniel Weintraub; Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-04       Impact factor: 4.105

6.  Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects.

Authors:  Benjamin R Underwood; Chris Fox
Journal:  Evid Based Med       Date:  2014-05-13

7.  Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2.

Authors:  Crystal V Flynn Longmire; Lea T Drye; Constantine E Frangakis; Barbara K Martin; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2014-01       Impact factor: 4.105

8.  Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.

Authors:  A P Auchus; C Bissey-Black
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

9.  Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

Authors:  Constantine G Lyketsos; Lourdes DelCampo; Martin Steinberg; Quincy Miles; Cynthia D Steele; Cynthia Munro; Alva S Baker; Jeannie-Marie E Sheppard; Constantine Frangakis; Jason Brandt; Peter V Rabins
Journal:  Arch Gen Psychiatry       Date:  2003-07

Review 10.  Depression in Alzheimer's disease: overview and treatment.

Authors:  Constantine G Lyketsos; Jason Olin
Journal:  Biol Psychiatry       Date:  2002-08-01       Impact factor: 13.382

View more
  5 in total

Review 1.  Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?

Authors:  Andrew H Ford; Osvaldo P Almeida
Journal:  Drugs Aging       Date:  2017-02       Impact factor: 3.923

Review 2.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 3.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 4.  Dementia Care at End of Life: Current Approaches.

Authors:  Mairead M Bartley; Laura Suarez; Reem M A Shafi; Joshua M Baruth; Amanda J M Benarroch; Maria I Lapid
Journal:  Curr Psychiatry Rep       Date:  2018-06-23       Impact factor: 5.285

Review 5.  The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions.

Authors:  Rachel M Keszycki; Daniel W Fisher; Hongxin Dong
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.